Abstract
Osteoarthritis (OA) and rheumatoid arthritis (RA) are the most prevalent of all the rheumatic diseases and currently, there are no reliable biochemical measures for early diagnosis or predicting who is likely to progress. Early diagnosis is important for making decisions on treatment options and for better management of patients. This narrative review highlights the first-generation biomarkers identified over the last 2 decades and focuses on the discovery and validation of candidate OA biomarkers from recent mass spectrometry-based proteomic studies for diagnosis and monitoring disease outcomes in human. It discusses the challenges and opportunities for discovery of novel biomarkers, progress in the development of techniques for measuring biomarkers, and provide directions for future discovery and validation of biomarkers for OA and RA.
| Original language | English |
|---|---|
| Journal | Biomarkers in Medicine |
| Early online date | 4 Oct 2017 |
| DOIs | |
| Publication status | E-pub ahead of print - 4 Oct 2017 |
Keywords
- Biomarkers
- Proteomics
- Mass Spectrometry
- Osteoarthritis
- Rheumatoid Arthritis
Access to Document
- Full-text PDF (accepted author manuscript)
This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Future Medicine at https://www.futuremedicine.com/doi/10.2217/bmm-2016-0374. Please refer to any applicable terms of use of the publisher.
Handle.net
Fingerprint
Dive into the research topics of 'Opportunities and challenges for the discovery and validation of biomarkers for common arthritic diseases'. Together they form a unique fingerprint.Profiles
-
Dr Mohammed Sharif
- Bristol Medical School (THS) - Honorary Senior Lecturer
Person: Honorary and Visiting Academic